ReviewNature reviews. Nephrology2015
Treatment of severe lupus nephritis: the new horizon.
Review in Nature reviews. Nephrology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 94 citations in OpenAlex.
- Treatment for lupus nephritis: an overview of systematic reviews and meta-analyses.Rheumatology international · 2017Pooled it
- A prospective study to compare the efficacy and safety of glucocorticoid-free maintenance therapy versus low-dose glucocorticoid maintenance therapy for lupus nephritis-a pilot, single-center, randomized controlled study.Clinical rheumatology · 2026Trial
- Mycophenolate Mofetil and New-Onset Systemic Lupus Erythematosus: A Randomized Clinical Trial.JAMA network open · 2024Trial
- Dan Bai Xiao Formula combined with glucocorticoids and cyclophosphamide for pediatric lupus nephritis: A pilot prospective study.World journal of clinical cases · 2022Trial
- Treatment patterns, treat-to-target goals and clinical outcomes of patients with active lupus nephritis: real-world evidence from a multicentre cohort study.Arthritis research & therapy · 2026Article
- Identification and validation of key autophagy-related genes in Lupus nephritis.Clinical rheumatology · 2026Article
- Cre-driven tdTomato expression unexpectedly confers resistance to peripheral but not central lupus in dLckCre mice.Journal of translational autoimmunity · 2025Article
- IgA Vasculitis (Henoch-Schönlein Purpura): An Update on Treatment.Journal of clinical medicine · 2024Review
- Cluster of differentiation-44 as a novel biomarker of lupus nephritis and its role in kidney inflammation and fibrosis.Frontiers in immunology · 2024Article
- Clinical research progress of novel biologics for the treatment of lupus nephritis.Clinical and experimental medicine · 2023Review
- Endothelial cell activation and glycocalyx shedding - potential as biomarkers in patients with lupus nephritis.Frontiers in immunology · 2023Review
- GBP2 acts as a member of the interferon signalling pathway in lupus nephritis.BMC immunology · 2022Article
- New Treatment Options in Lupus Nephritis.Archivum immunologiae et therapiae experimentalis · 2022Review
- Effect of Combined Mycophenolate and Rapamycin Treatment on Kidney Fibrosis in Murine Lupus Nephritis.Frontiers in pharmacology · 2022Article
- Effectiveness and safety of Belimumab combined with standard therapy in severe active lupus nephritis requiring kidney replacement therapy: A case report and literature review.Frontiers in immunology · 2022Review
- Clinical analysis of multi-target treatment for complex lupus nephritis.American journal of translational research · 2022Article
- Role of Dexamethasone and Methylprednisolone Corticosteroids in Coronavirus Disease 2019 Hospitalized Patients: A Review.Frontiers in microbiology · 2022Review
- Punicalagin Ameliorates Lupus Nephritis via Inhibition of PAR2.International journal of molecular sciences · 2020Article
- A review of advances in the understanding of lupus nephritis pathogenesis as a basis for emerging therapies.F1000Research · 2020Review
- Treatment Patterns and Health Care Costs of Lupus Nephritis in a United States Payer Population.Open access rheumatology : research and reviews · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lupus nephritis is a common and severe manifestation of systemic lupus erythematosus, and an important cause of both acute kidney injury and end-stage renal disease. Despite its aggressive course, lupus nephritis is amenable to treatment in the majority of patients. The paradigm of immunosuppressive treatment for lupus nephritis has evolved over the past few decades from corticosteroids alone to corticosteroids combined with cyclophosphamide. Sequential treatment regimens using various agents have been formulated for induction and long-term maintenance therapy, and mycophenolate mofetil has emerged as a standard of care option for both induction and maintenance immunosuppressive treatment. The current era has witnessed the emergence of multiple novel therapeutic options, such as calcineurin inhibitors and biologic agents that target key pathogenetic mechanisms of lupus nephritis. Clinical outcomes have improved in parallel with these therapeutic advances. This Review discusses the evidence in support of current standard of care immunosuppressive treatments and emerging therapies, and describes their roles and relative merits in the management of patients with lupus nephritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.